Haqq Christopher
EVP, R&D & Chief Scientific Of at ATRA
- Sold, on record
- $7.6M
- Dollars the filings state
- Form 4 sales
- 34
- Latest Feb 15, 2019
- Form 144 notices
- 0
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 1
- Filed as an executive or holder
Companies
- ATRAAtara Biotherapeutics, Inc.EVP, R&D & Chief Scientific Of
Sales by reason
0
Routine
29
Plan not stated
0
No plan
5
Unusual
Form 4 sales per year, every sale on record.
Timeline
- Feb 15, 2019Plan not stated
Sold 0.3% of their holdings
$31k775 shares at $39.59
- Feb 11, 2019Plan not stated
Sold 4.9% of their holdings
$539k13,975 shares at $38.55
- Feb 6, 2019Plan not stated
Sold 4.3% of their holdings
$478k12,375 shares at $38.62
- Nov 15, 2018Plan not stated
Sold 0.3% of their holdings
$26k775 shares at $33.81
- Sep 26, 2018Plan not stated
Sold 4.5% of their holdings
$582k13,500 shares at $43.08
- Sep 25, 2018Unusual
Sold 9.5% of their holdings
$1.3M31,500 shares at $40.17
- Aug 15, 2018Plan not stated
Sold 0.2% of their holdings
$29k775 shares at $37.54
- May 15, 2018Unusual
Sold 7.2% of their holdings
$1.2M25,775 shares at $45.30
- Mar 26, 2018Unusual
Sold 5.2% of their holdings
$729k18,327 shares at $39.79
- Nov 15, 2017Plan not stated
Sold 0.5% of their holdings
$21k1,604 shares at $13.36
10 of 34
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Jul 17, 2026 | ELTX | Officer | AwardedStock Option (Right to Buy) | 64,643 | 64,643 | SEC | ||
| Feb 2, 2026 | Feb 3, 2026 | ELTX | Officer | AwardedStock Option (Right to Buy) | 50,900 | 50,900 | SEC | ||
| Feb 2, 2026 | Feb 3, 2026 | ELTX | Officer | Awarded | 25,400 | 57,381 | SEC | ||
| Feb 3, 2025 | Feb 4, 2025 | ELTX | Officer | AwardedStock Option (Right to Buy) | 44,000 | 44,000 | SEC | ||
| Sep 30, 2024 | Oct 2, 2024 | ELTX | Officer | AwardedStock Option (Right to Buy) | 28,200 | 28,200 | SEC | ||
| Feb 1, 2024 | Feb 5, 2024 | ELTX | Officer | AwardedStock Option (right to buy) | 28,200 | 28,200 | SEC | ||
| Aug 11, 2021 | Aug 13, 2021 | SRZN | Other | Returned to the companyClass B Ordinary Shares | 30,000 | 0 | SEC | ||
| Aug 11, 2021 | Aug 13, 2021 | SRZN | Other | Awarded | 30,000 | 30,000 | SEC | ||
| Feb 15, 2019 | Feb 19, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 775 | $39.59 | $31k | 271,943 | SEC |
| Feb 11, 2019 | Feb 11, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 13,975 | $38.55 | $539k | 272,718 | SEC |
| Feb 6, 2019 | Feb 8, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 12,375 | $38.62 | $478k | 273,205 | SEC |
| Feb 6, 2019 | Feb 8, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Withheld for tax | 1,512 | $38.47 | $58k | 271,693 | SEC |
| Feb 6, 2019 | Feb 8, 2019 | ATRA | EVP, R&D & Chief Scientific Of | AwardedEmployee Stock Option (Right to Buy) | 30,000 | 30,000 | SEC | ||
| Feb 6, 2019 | Feb 8, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Awarded | 15,000 | 286,693 | SEC | ||
| Nov 15, 2018 | Nov 15, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 775 | $33.81 | $26k | 285,580 | SEC |
| Sep 26, 2018 | Sep 27, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 13,500 | $43.08 | $582k | 286,355 | SEC |
| Sep 25, 2018 | Sep 25, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 31,500 | $40.17 | $1.3M | 299,855 | SEC |
| Aug 15, 2018 | Aug 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 775 | $37.54 | $29k | 331,355 | SEC |
| May 15, 2018 | May 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 25,775 | $45.30 | $1.2M | 332,130 | SEC |
| May 15, 2018 | May 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledEmployee Stock Option (Right to Buy) | 25,000 | 25,000 | SEC | ||
| May 15, 2018 | May 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 25,000 | $11.00 | $275k | 357,905 | SEC |
| Mar 26, 2018 | Mar 27, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 18,327 | $39.79 | $729k | 332,905 | SEC |
| Feb 15, 2018 | Feb 20, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledRestricted Stock Units | 553 | 0 | SEC | ||
| Feb 15, 2018 | Feb 20, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 553 | 351,232 | SEC | ||
| Feb 9, 2018 | Feb 12, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Withheld for tax | 4,925 | $41.70 | $205k | 350,679 | SEC |
| Feb 6, 2018 | Feb 8, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Withheld for tax | 4,426 | $35.80 | $158k | 355,604 | SEC |
| Feb 6, 2018 | Feb 8, 2018 | ATRA | EVP, R&D & Chief Scientific Of | AwardedEmployee Stock Option (Right to Buy) | 35,000 | 35,000 | SEC | ||
| Feb 6, 2018 | Feb 8, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Awarded | 17,500 | 360,030 | SEC | ||
| Nov 15, 2017 | Nov 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 1,604 | $13.36 | $21k | 342,530 | SEC |
| Nov 15, 2017 | Nov 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledRestricted Stock Units | 829 | 553 | SEC | ||
| Nov 15, 2017 | Nov 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 829 | 344,134 | SEC | ||
| Oct 16, 2017 | Oct 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $14.35 | $86k | 343,305 | SEC |
| Sep 15, 2017 | Sep 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $15.30 | $92k | 349,305 | SEC |
| Aug 15, 2017 | Aug 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 7,604 | $14.75 | $112k | 355,305 | SEC |
| Aug 15, 2017 | Aug 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledRestricted Stock Units | 829 | 1,382 | SEC | ||
| Aug 15, 2017 | Aug 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 829 | 362,909 | SEC | ||
| Jul 17, 2017 | Jul 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $14.92 | $90k | 362,080 | SEC |
| Jun 15, 2017 | Jun 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $12.65 | $76k | 368,080 | SEC |
| May 15, 2017 | May 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 7,604 | $14.99 | $114k | 374,080 | SEC |
| May 15, 2017 | May 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledRestricted Stock Units | 829 | 2,211 | SEC | ||
| May 15, 2017 | May 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 829 | 381,684 | SEC | ||
| Apr 17, 2017 | Apr 19, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $17.28 | $104k | 380,855 | SEC |
| Mar 15, 2017 | Mar 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $19.60 | $118k | 386,855 | SEC |
| Feb 15, 2017 | Feb 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 7,604 | $15.49 | $118k | 392,855 | SEC |
| Feb 15, 2017 | Feb 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised or settledRestricted Stock Units | 829 | 3,040 | SEC | ||
| Feb 15, 2017 | Feb 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Exercised options | 829 | 400,459 | SEC | ||
| Feb 9, 2017 | Feb 10, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 13,975 | $15.46 | $216k | 399,630 | SEC |
| Feb 6, 2017 | Feb 8, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Awarded | 49,500 | 413,605 | SEC | ||
| Jan 17, 2017 | Jan 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Sold | 6,000 | $14.27 | $86k | 364,105 | SEC |
| Dec 15, 2016 | Dec 15, 2016 | ATRA | Chief Medical Officer | Sold | 6,000 | $15.40 | $92k | 370,105 | SEC |
Page 1
Sales and notices (34)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2019 | Feb 19, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 775 | $31k | 0.3% | Plan not stated | SEC |
| Feb 11, 2019 | Feb 11, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 13,975 | $539k | 4.9% | Plan not stated | SEC |
| Feb 6, 2019 | Feb 8, 2019 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 12,375 | $478k | 4.3% | Plan not stated | SEC |
| Nov 15, 2018 | Nov 15, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 775 | $26k | 0.3% | Plan not stated | SEC |
| Sep 26, 2018 | Sep 27, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 13,500 | $582k | 4.5% | Plan not stated | SEC |
| Sep 25, 2018 | Sep 25, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 31,500 | $1.3M | 9.5% | Unusual | SEC |
| Aug 15, 2018 | Aug 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 775 | $29k | 0.2% | Plan not stated | SEC |
| May 15, 2018 | May 16, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 25,775 | $1.2M | 7.2% | Unusual | SEC |
| Mar 26, 2018 | Mar 27, 2018 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 18,327 | $729k | 5.2% | Unusual | SEC |
| Nov 15, 2017 | Nov 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 1,604 | $21k | 0.5% | Plan not stated | SEC |
| Oct 16, 2017 | Oct 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $86k | 1.7% | Plan not stated | SEC |
| Sep 15, 2017 | Sep 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $92k | 1.7% | Plan not stated | SEC |
| Aug 15, 2017 | Aug 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 7,604 | $112k | 2.1% | Plan not stated | SEC |
| Jul 17, 2017 | Jul 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $90k | 1.6% | Plan not stated | SEC |
| Jun 15, 2017 | Jun 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $76k | 1.6% | Plan not stated | SEC |
| May 15, 2017 | May 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 7,604 | $114k | 2.0% | Plan not stated | SEC |
| Apr 17, 2017 | Apr 19, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $104k | 1.6% | Plan not stated | SEC |
| Mar 15, 2017 | Mar 17, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $118k | 1.5% | Plan not stated | SEC |
| Feb 15, 2017 | Feb 16, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 7,604 | $118k | 1.9% | Unusual | SEC |
| Feb 9, 2017 | Feb 10, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 13,975 | $216k | 3.4% | Unusual | SEC |
| Jan 17, 2017 | Jan 18, 2017 | ATRA | EVP, R&D & Chief Scientific Of | Form 4 sale | 6,000 | $86k | 1.6% | Plan not stated | SEC |
| Dec 15, 2016 | Dec 15, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 6,000 | $92k | 1.6% | Plan not stated | SEC |
| Nov 21, 2016 | Nov 22, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 7,068 | $126k | 1.8% | Plan not stated | SEC |
| Nov 15, 2016 | Nov 17, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 1,604 | $32k | 0.4% | Plan not stated | SEC |
| Aug 15, 2016 | Aug 17, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 1,346 | $30k | 0.5% | Plan not stated | SEC |
| May 16, 2016 | May 18, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 1,605 | $25k | 0.5% | Plan not stated | SEC |
| Feb 16, 2016 | Feb 18, 2016 | ATRA | Chief Medical Officer | Form 4 sale | 3,208 | $49k | 1.1% | Plan not stated | SEC |
| Aug 31, 2015 | Sep 1, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 5,000 | $210k | 2.0% | Plan not stated | SEC |
| Aug 17, 2015 | Aug 19, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 1,604 | $74k | 0.6% | Plan not stated | SEC |
| Jul 31, 2015 | Aug 3, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 2,500 | $139k | 1.0% | Plan not stated | SEC |
| Jul 15, 2015 | Jul 15, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 2,500 | $157k | 1.0% | Plan not stated | SEC |
| Jul 1, 2015 | Jul 2, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 2,500 | $129k | 1.0% | Plan not stated | SEC |
| Jun 15, 2015 | Jun 16, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 7,500 | $348k | 2.9% | Plan not stated | SEC |
| Jun 1, 2015 | Jun 1, 2015 | ATRA | Chief Medical Officer | Form 4 sale | 2,500 | $104k | 0.9% | Plan not stated | SEC |